A randomized, placebo-controlled, double-blind, multi-center, proof of concept study will assess the tolerability and preliminary efficacy of OCU310 for the treatment of Dry Eye Disease (DED).

Trial Profile

A randomized, placebo-controlled, double-blind, multi-center, proof of concept study will assess the tolerability and preliminary efficacy of OCU310 for the treatment of Dry Eye Disease (DED).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Brimonidine (Primary)
  • Indications Dry eyes
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 28 Sep 2017 New trial record
    • 25 Sep 2017 According to an Ocugen media release, first patient has been dosed.
    • 25 Sep 2017 According to an Ocugen Investigational New Drug (IND) application has been accepted.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top